Search Result "ezetimibe. proprotein convertase subtilisin/kexin type 9"
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and LDL Lowering in the Contemporary Management of Dyslipidemia
Journal: Cardiovascular & Hematological Agents in Medicinal Chemistry
Volume: 11 Issue: 4 Year: 2013 Page: 281-288
Author(s): Maryna Popp Switzer,Azikiwe C. Nwosu,Zinnia San Juan,Debabrata Mukherjee
Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors to Reduce Cardiovascular Inflammation and Outcomes
Journal: Current Medicinal Chemistry
Volume: 24 Issue: 1 Year: 2017 Page: 1403-1416
Author(s): Luca Liberale,Fabrizio Montecucco,Giovanni G. Camici,Franco Dallegri,Alessandra Vecchie,Federico Carbone,Aldo Bonaventura
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events
Journal: Cardiovascular & Hematological Agents in Medicinal Chemistry
Volume: 14 Issue: 2 Year: 2016 Page: 94-100
Author(s): Muharrem Akin,Thomas Skripuletz,L. Christian Napp,Dominik Berliner,Ibrahim Akin,Arash Haghikia,Elvan Akin,Johann Bauersachs
The Lipid Hypothesis: From Resins to Proprotein Convertase Subtilisin/Kexin Type-9 Inhibitors
Ebook: Frontiers in Cardiovascular Drug Discovery
Volume: 5 Year: 2020
Author(s): Sudarshan Ramachandran,Mithun Bhartia,Carola S. König
Doi: 10.2174/9789811413247120050003
PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?
Journal: Current Pharmaceutical Design
Volume: 19 Issue: 2 Year: 2013 Page: 3869-3877
Author(s): Maciej Banach, Manfredi Rizzo, Milan Obradovic, Giuseppe Montalto, Jacek Rysz, Dimitri P. Mikhailidis, Esma R. Isenovic
Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia and other Pathologies
Journal: Current Pharmaceutical Design
Volume: 19 Issue: 1 Year: 2013 Page: 3161-3172
Author(s): Nabil G. Seidah
PCSK9 Inhibitors and Ezetimibe Monotherapy in Patients Not Receiving Statins: A Meta-Analysis of Randomized Trials
Journal: Current Vascular Pharmacology
Volume: 19 Issue: 4 Year: 2021 Page: 390-397
Author(s): Benjamin Benhuri,Hiroki Ueyama,Hisato Takagi,Alexandros Briasoulis,Toshiki Kuno
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, Reality or Dream in Managing Patients with Cardiovascular Disease
Journal: Current Drug Metabolism
Volume: 20 Issue: 1 Year: 2019 Page: 72-82
Author(s): Mohammad Alkhalil
Hypolipidaemic Drug Treatment: Yesterday is Not Gone Yet, Today is Challenging and Tomorrow is Coming Soon; let us Combine them all
Journal: Current Pharmaceutical Design
Volume: 20 Issue: 4 Year: 2014 Page: 6350-6357
Author(s): Vasilios G. Athyros, Konstantinos Tziomalos, Asterios Karagiannis, Dimitri P. Mikhailidis
Dyslipidaemias and Cardiovascular Disease: Focus on the Role of PCSK9 Inhibitors
Journal: Current Medicinal Chemistry
Volume: 27 Issue: 27 Year: 2020 Page: 4494-4521
Author(s): Olga Panagiotopoulou,Scott T. Chiesa,Dimitrios Tousoulis,Marietta Charakida